JP2025509613A5 - - Google Patents
Info
- Publication number
- JP2025509613A5 JP2025509613A5 JP2024554864A JP2024554864A JP2025509613A5 JP 2025509613 A5 JP2025509613 A5 JP 2025509613A5 JP 2024554864 A JP2024554864 A JP 2024554864A JP 2024554864 A JP2024554864 A JP 2024554864A JP 2025509613 A5 JP2025509613 A5 JP 2025509613A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- approximately
- administered
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263320347P | 2022-03-16 | 2022-03-16 | |
| US63/320,347 | 2022-03-16 | ||
| US202263340726P | 2022-05-11 | 2022-05-11 | |
| US63/340,726 | 2022-05-11 | ||
| PCT/US2023/064550 WO2023178255A1 (en) | 2022-03-16 | 2023-03-16 | Combinations comprising metap2 inhibitors for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509613A JP2025509613A (ja) | 2025-04-11 |
| JP2025509613A5 true JP2025509613A5 (cg-RX-API-DMAC7.html) | 2026-03-26 |
Family
ID=85979451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024554864A Pending JP2025509613A (ja) | 2022-03-16 | 2023-03-16 | がん治療のためのＭｅｔＡＰ２阻害剤を含む組み合わせ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20260014194A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4493181A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025509613A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240164549A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119300818A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023235307A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3245962A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024011197A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023178255A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021378944A1 (en) * | 2020-11-11 | 2023-06-15 | Syndevrx, Inc. | Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3177603T3 (en) * | 2014-08-04 | 2019-01-14 | Merck Patent Gmbh | PYRROLIDINE UNDERIVATIVES AS METAP-2 INHIBITORS |
| US11612577B2 (en) * | 2018-10-26 | 2023-03-28 | Syndevrx, Inc. | Biomarkers of METAP2 inhibitors and applications thereof |
-
2023
- 2023-03-16 WO PCT/US2023/064550 patent/WO2023178255A1/en not_active Ceased
- 2023-03-16 KR KR1020247034327A patent/KR20240164549A/ko active Pending
- 2023-03-16 EP EP23716148.4A patent/EP4493181A1/en active Pending
- 2023-03-16 CN CN202380040935.XA patent/CN119300818A/zh active Pending
- 2023-03-16 MX MX2024011197A patent/MX2024011197A/es unknown
- 2023-03-16 CA CA3245962A patent/CA3245962A1/en active Pending
- 2023-03-16 AU AU2023235307A patent/AU2023235307A1/en active Pending
- 2023-03-16 US US18/846,365 patent/US20260014194A1/en active Pending
- 2023-03-16 JP JP2024554864A patent/JP2025509613A/ja active Pending